Development and validation of a clinical predictive model for high-volume lymph node metastasis of papillary thyroid carcinoma

Abstract

Abstract The central lymph node metastasis (CLNM) status in the cervical region serves as a pivotal determinant for the extent of surgical intervention and prognosis in papillary thyroid carcinoma (PTC). This paper seeks to devise and validate a predictive model based on clinical parameters for the early anticipation of high-volume CLNM (hv-CLNM, > 5 nodes) in high-risk patients. A retrospective analysis of the pathological and clinical data of patients with PTC who underwent surgical treatment at Medical Centers A and B was conducted. The data from Center A was randomly divided into training and validation sets in an 8:2 ratio, with those from Center B serving as the test set. Multifactor logistic regression was harnessed in the training set to select variables and construct a predictive model. The generalization ability of the model was assessed in the validation and test sets. The model was evaluated through the receiver operating characteristic area under the curve (AUC) to predict the efficiency of hv-CLNM. The goodness of fit of the model was examined via the Brier verification technique. The incidence of hv-CLNM in 5897 PTC patients attained 4.8%. The occurrence rates in males and females were 9.4% (128/1365) and 3.4% (156/4532), respectively. Multifactor logistic regression unraveled male gender (OR = 2.17, p 10 mm) as 0.803 (0.757–0.85) and 0.747 (0.709–0.785), age groups (≤ 31 years and > 31 years) as 0.778 (0.720–0.881) and 0.837 (0.806–0.867), multifocal and solitary cases as 0.803 (0.767–0.838) and 0.809 (0.769–0.849), and Hashimoto’s thyroiditis (HT) and non-HT cases as 0.845 (0.793–0.897) and 0.845 (0.819–0.871). Male gender, multifocality, and larger lesion size are risk factors for hv-CLNM in PTC patients, whereas age serves as a protective factor. The clinical predictive model developed in this research facilitates the early identification of high-risk patients for hv-CLNM, thereby assisting physicians in more efficacious risk stratification management for PTC patients.

Keywords

• Papillary thyroid carcinoma
• Central lymph node metastasis
• High volume
• Clinical predictive model